Dyne Therapeutics (NASDAQ: DYN) CCO sells shares to cover taxes
Rhea-AI Filing Summary
Dyne Therapeutics, Inc. officer Johanna Friedl-Naderer, Chief Commercial Officer, reported an automatic sale of 226 shares of common stock on 2026-08-13 at a weighted average price of $26.28 per share. The shares were sold to satisfy tax withholding obligations arising from vesting of restricted stock units under a Rule 10b5-1 binding contract, and not as a discretionary trade. Following this transaction, she directly holds 153,982 shares, which include 119,928 unvested RSUs.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 226 shares
Net Sell
1 txn
Insider
Friedl-Naderer Johanna
Role
Chief Commercial Officer
Sold
226 shs ($6K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2, F3 | 226 | $26.28 | $6K |
Holdings After Transaction:
Common Stock — 153,982 shares (Direct)
Footnotes (3)
- F1. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
- F3. Includes 119,928 unvested RSUs.
Key Figures
Shares Sold: 226 shares
Weighted Average Sale Price: $26.28 per share
Shares Held After Transaction: 153,982 shares
+2 more
5 metrics
Shares Sold
226 shares
Common stock sold on 2026-08-13 to satisfy tax withholding
Weighted Average Sale Price
$26.28 per share
Weighted average price for the 226 shares sold, within $26.17–$26.39 range
Shares Held After Transaction
153,982 shares
Direct ownership of Dyne Therapeutics common stock following the sale
Unvested RSUs Included
119,928 RSUs
Unvested restricted stock units included in post-transaction holdings
Transaction Date
2026-08-13
Date of automatic sale to cover tax withholding
Key Terms
Rule 10b5-1, restricted stock units, weighted average price, tax withholding obligations
4 terms
Rule 10b5-1 regulatory
"constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
restricted stock units financial
"vesting of restricted stock units granted to the Reporting Person on February 12, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
tax withholding obligations financial
"sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting"
FAQ
What insider transaction did DYN executive Johanna Friedl-Naderer report?
Johanna Friedl-Naderer reported a sale of 226 Dyne Therapeutics (DYN) common shares on 2026-08-13. The sale was to cover tax withholding from vesting restricted stock units, under a pre-arranged Rule 10b5-1 binding contract.
Was the DYN insider sale by Johanna Friedl-Naderer a discretionary trade?
No. The filing states the 226-share sale was an automatic sale to satisfy tax withholding from RSU vesting. It was executed under a binding Rule 10b5-1 contract and is described as not a discretionary trade.
What is the reason for the insider sale reported for DYN on 2026-08-13?
The sale of 226 DYN shares was to satisfy tax withholding obligations related to the vesting of restricted stock units granted on February 12, 2026. It was carried out automatically under the RSU agreement.
Does the Form 4 for DYN indicate any remaining unvested RSUs for the insider?
Yes. The filing specifies that post-transaction holdings of 153,982 shares include 119,928 unvested RSUs. These restricted stock units continue to be subject to vesting as outlined in the applicable award agreements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
